Developing a curative gene therapy for Crigler-Najjar syndrome
1.1.2018 – 31.12.2022

Duration

6.25 M €

Funding

11 Partners from 6 countries

Consortium

The Vision of CureCN

The overall vision of the European research project CureCN is to provide a curative gene therapy for the ultra-rare Crigler-Najjar syndrome (CN). CN is a life-threatening, so far incurable liver disease that affects about one in a million individuals at birth.

The CureCN consortium joins forces to prove the safety and efficacy of the gene therapy in a clinical trial and to make the treatment available to patients. The project is funded by the European Framework Programme for Research and Innovation Horizon 2020 with a total budget of € 6.25 million.

Read more

Partners

The CureCN consortium brings together 11 European partners from academia, hospitals, healthcare companies and patient organisations to fight the so far incurable liver disease Crigler-Najjar (CN). Together, they aim to validate a gene therapy within a clinical trial to provide the first curative treatment against CN.

Read more

Latest News

Information for Patients

CureCN is a patient-driven research endeavour comprising all active Crigler-Najjar patient organisations in Europe. You are a patient, a family member or a friend of a person living with CN? Please find more information about the project and how CureCN and the patient organisations involved can provide support and advice to improve the quality of life for people with CN.

Read more

Videos